We were honored when Deloitte contacted Sapient to contribute our technological insights and perspectives to this report, specifically related to how biotech innovations like our next-generation mass spectrometry platform and large-scale multi-omics approaches are accelerating therapeutic discovery, transforming treatments, and helping people live longer and better lives.
Deloitte points out that health care is under construction, driven by a convergence of groundbreaking innovations to generate more biological data than ever and sociocultural shifts that have reframed how consumers view their health care journeys. Balancing the two is a critical challenge for the next human health advancements. As Dr. Mo Jain, Founder and CEO of Sapient, notes in the report, “Generating more data is not the end goal; the end goal is generating more insights that can be acted on.”
Read the full report to see some of the key technologies and trends working to bridge data and insight gaps to make drug development more effective and efficient than ever before.